Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes

Rhea-AI Summary

Senseonics Holdings (NYSE: SENS) announced an upcoming analyst event on June 21, 2025, at 8:00am CT at the Marriot Marquis Chicago, coinciding with ADA 2025. The event will showcase their FDA-approved Eversense 365 Continuous Glucose Monitoring system for diabetes patients 18 and older. Key speakers include company management, Brian Hansen from Ascencia Diabetes Care discussing the commercial launch, and Gary Graf from Cotton-O'Neil discussing system experience and insertion procedures. Management will also address their partnership with Sequel for the twiist automated insulin delivery pump integration and future implantable CGM technology developments. The event will be available both in-person and virtually, concluding with a Q&A session.

GERMANTOWN, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it will host an in-person and virtual analyst event in conjunction with the American Diabetes Association 85th Scientific Sessions (ADA 2025), on Saturday, June 21, 2025 at 8:00am CT at the Marriot Marquis Chicago. To register, click here.

The event will feature company management who will discuss the next-generation Eversense® 365 Continuous Glucose Monitoring (CGM) system, approved by the U.S. Food and Drug Administration (FDA) for people with diabetes aged 18 years and older.

Along with comments from management, the event will feature Brian Hansen (Ascencia Diabetes Care), who will speak to the commercial launch of Eversense 365, and Gary Graf, MSN, APRN-C (Cotton-O’Neil Diabetes and Endocrinology Center), who will speak to experience with the Eversense system and the insertion procedure. Company management will also discuss the recently announced partnership with Sequel to integrate with the twiist automated insulin delivery pump and plans to advance its pipeline of implantable CGM technology.

A live question and answer session will follow the formal presentations.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

INVESTOR CONTACT:
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com

FAQ

When and where is Senseonics (SENS) hosting its analyst event at ADA 2025?

Senseonics is hosting the analyst event on Saturday, June 21, 2025, at 8:00am CT at the Marriot Marquis Chicago.

What will be discussed at the Senseonics (SENS) analyst event?

The event will cover the Eversense 365 CGM system, its commercial launch, insertion procedure experiences, and the partnership with Sequel for twiist insulin pump integration.

Who are the key speakers at the Senseonics (SENS) ADA 2025 analyst event?

Key speakers include company management, Brian Hansen from Ascencia Diabetes Care, and Gary Graf from Cotton-O'Neil Diabetes and Endocrinology Center.

What is the Eversense 365 CGM system by Senseonics (SENS)?

Eversense 365 is an FDA-approved, long-term, implantable continuous glucose monitoring system designed for people with diabetes aged 18 years and older.

How can investors attend the Senseonics (SENS) analyst event at ADA 2025?

Investors can attend either in-person at the Marriot Marquis Chicago or virtually by registering through the provided link.